The locus coeruleus (LC) is linked to the development and pathophysiology of neurodegenerative diseases such as Alzheimer's disease (AD). Magnetic resonance imaging-based LC features have shown potential to assess LC integrity in vivo. We present a deep learning-based LC segmentation and feature extraction method called Ensemble-based Locus Coeruleus Segmentation Network (ELSI-Net) and apply it to healthy aging and AD dementia datasets. Agreement to expert raters and previously published LC atlases were assessed. We aimed to reproduce previously reported differences in LC integrity in aging and AD dementia and correlate extracted features to cerebrospinal fluid (CSF) biomarkers of AD pathology. ELSI-Net demonstrated high agreement to expert raters and published atlases. Previously reported group differences in LC integrity were detected and correlations to CSF biomarkers were found. Although we found excellent performance, further evaluations on more diverse datasets from clinical cohorts are required for a conclusive assessment of ELSI-Net's general applicability. We provide a thorough evaluation of a fully automatic locus coeruleus (LC) segmentation method termed Ensemble-based Locus Coeruleus Segmentation Network (ELSI-Net) in aging and Alzheimer's disease (AD) dementia.ELSI-Net outperforms previous work and shows high agreement with manual ratings and previously published LC atlases.ELSI-Net replicates previously shown LC group differences in aging and AD.ELSI-Net's LC mask volume correlates with cerebrospinal fluid biomarkers of AD pathology.

Machine learning (ML) classification of myocardial scarring in cardiac MRI is often hindered by limited explainability, particularly with convolutional neural networks (CNNs). To address this, we developed One Match (OM), an algorithm that builds on template matching to improve on both the explainability and performance of ML myocardial scaring classification. By incorporating OM, we aim to foster trust in AI models for medical diagnostics and demonstrate that improved interpretability does not have to compromise classification accuracy. Using a cardiac MRI dataset from 279 patients, this study evaluates One Match, which classifies myocardial scarring in images by matching each image to a set of labeled template images. It uses the highest correlation score from these matches for classification and is compared to a traditional sequential CNN. Enhancements such as autodidactic enhancement (AE) and patient-level classifications (PLCs) were applied to improve the predictive accuracy of both methods. Results are reported as follows: accuracy, sensitivity, specificity, precision, and F1-score. The highest classification performance was observed with the OM algorithm when enhanced by both AE and PLCs, 95.3% accuracy, 92.3% sensitivity, 96.7% specificity, 92.3% precision, and 92.3% F1-score, marking a significant improvement over the base configurations. AE alone had a positive impact on OM increasing accuracy from 89.0% to 93.2%, but decreased the accuracy of the CNN from 85.3% to 82.9%. In contrast, PLCs improved accuracy for both the CNN and OM, raising the CNN's accuracy by 4.2% and OM's by 7.4%. This study demonstrates the effectiveness of OM in classifying myocardial scars, particularly when enhanced with AE and PLCs. The interpretability of OM also enabled the examination of misclassifications, providing insights that could accelerate development and foster greater trust among clinical stakeholders.

<b>Background:</b> No robust biomarkers have been identified to predict the efficacy of programmed cell death protein 1 (PD-1) inhibitors in patients with locoregionally advanced nasopharyngeal carcinoma (LANPC). We aimed to develop radiomic models using pre-immunotherapy MRI to predict the response to PD-1 inhibitors and the patient prognosis. <b>Methods:</b> This study included 246 LANPC patients (training cohort, <i>n</i> = 117; external test cohort, <i>n</i> = 129) from 10 centers. The best-performing machine learning classifier was employed to create the radiomic models. A combined model was constructed by integrating clinical and radiomic data. A radiomic interpretability study was performed with whole slide images (WSIs) stained with hematoxylin and eosin (H&E) and immunohistochemistry (IHC). A total of 150 patient-level nuclear morphological features (NMFs) and 12 cell spatial distribution features (CSDFs) were extracted from WSIs. The correlation between the radiomic and pathological features was assessed using Spearman correlation analysis. <b>Results:</b> The radiomic model outperformed the clinical and combined models in predicting treatment response (area under the curve: 0.760 vs. 0.559 vs. 0.652). For overall survival estimation, the combined model performed comparably to the radiomic model but outperformed the clinical model (concordance index: 0.858 vs. 0.812 vs. 0.664). Six treatment response-related radiomic features correlated with 50 H&E-derived (146 pairs, |<i>r</i>|= 0.31 to 0.46) and 2 to 26 IHC-derived NMF, particularly for CD45RO (69 pairs, |<i>r</i>|= 0.31 to 0.48), CD8 (84, |<i>r</i>|= 0.30 to 0.59), PD-L1 (73, |<i>r</i>|= 0.32 to 0.48), and CD163 (53, |<i>r</i>| = 0.32 to 0.59). Eight prognostic radiomic features correlated with 11 H&E-derived (16 pairs, |<i>r</i>|= 0.48 to 0.61) and 2 to 31 IHC-derived NMF, particularly for PD-L1 (80 pairs, |<i>r</i>|= 0.44 to 0.64), CD45RO (65, |<i>r</i>|= 0.42 to 0.67), CD19 (35, |<i>r</i>|= 0.44 to 0.58), CD66b (61, |<i>r</i>| = 0.42 to 0.67), and FOXP3 (21, |<i>r</i>| = 0.41 to 0.71). In contrast, fewer CSDFs exhibited correlations with specific radiomic features. <b>Conclusion:</b> The radiomic model and combined model are feasible in predicting immunotherapy response and outcomes in LANPC patients. The radiology-pathology correlation suggests a potential biological basis for the predictive models.

Currently, there are inconsistencies among different studies on preoperative prediction of Cytokeratin 19 (CK19) expression in HCC using traditional imaging, radiomics, and deep learning. We aimed to systematically analyze and compare the performance of non-invasive methods for predicting CK19-positive HCC, thereby providing insights for the stratified management of HCC patients. A comprehensive literature search was conducted in PubMed, EMBASE, Web of Science, and the Cochrane Library from inception to February 2025. Two investigators independently screened and extracted data based on inclusion and exclusion criteria. Eligible studies were included, and key findings were summarized in tables to provide a clear overview. Ultimately, 22 studies involving 3395 HCC patients were included. 72.7% (16/22) focused on traditional imaging, 36.4% (8/22) on radiomics, 9.1% (2/22) on deep learning, and 54.5% (12/22) on combined models. The magnetic resonance imaging was the most commonly used imaging modality (19/22), and over half of the studies (12/22) were published between 2022 and 2025. Moreover, 27.3% (6/22) were multicenter studies, 36.4% (8/22) included a validation set, and only 13.6% (3/22) were prospective. The area under the curve (AUC) range of using clinical and traditional imaging was 0.560 to 0.917. The AUC ranges of radiomics were 0.648 to 0.951, and the AUC ranges of deep learning were 0.718 to 0.820. Notably, the AUC ranges of combined models of clinical, imaging, radiomics and deep learning were 0.614 to 0.995. Nevertheless, the multicenter external data were limited, with only 13.6% (3/22) incorporating validation. The combined model integrating traditional imaging, radiomics and deep learning achieves excellent potential and performance for predicting CK19 in HCC. Based on current limitations, future research should focus on building an easy-to-use dynamic online tool, combining multicenter-multimodal imaging and advanced deep learning approaches to enhance the accuracy and robustness of model predictions.

Magnetic Resonance Imaging (MRI) is a crucial diagnostic tool in medicine, widely used to detect and assess various health conditions. Different MRI sequences, such as T1-weighted, T2-weighted, and FLAIR, serve distinct roles by highlighting different tissue characteristics and contrasts. However, distinguishing them based solely on the description file is currently impossible due to confusing or incorrect annotations. Additionally, there is a notable lack of effective tools to differentiate these sequences. In response, we developed a deep learning-based toolkit tailored for small, unrefined MRI datasets. This toolkit enables precise sequence classification and delivers performance comparable to systems trained on large, meticulously curated datasets. Utilizing lightweight model architectures and incorporating a voting ensemble method, the toolkit enhances accuracy and stability. It achieves a 99% accuracy rate using only 10% of the data typically required in other research. The code is available at https://github.com/JinqianPan/MRISeqClassifier.

Prostate cancer is a common malignancy in men, and accurately distinguishing between benign and malignant nodules at an early stage is crucial for optimizing treatment. Multimodal imaging (such as ADC and T2) plays an important role in the diagnosis of prostate cancer, but effectively combining these imaging features for accurate classification remains a challenge. This retrospective study included MRI data from 199 prostate cancer patients. Radiomic features from both the tumor and peritumoral regions were extracted, and a random forest model was used to select the most contributive features for classification. Three machine learning models-Random Forest, XGBoost, and Extra Trees-were then constructed and trained on four different feature combinations (tumor ADC, tumor T2, tumor ADC+T2, and tumor + peritumoral ADC+T2). The model incorporating multimodal imaging features and peritumoral characteristics showed superior classification performance. The Extra Trees model outperformed the others across all feature combinations, particularly in the tumor + peritumoral ADC+T2 group, where the AUC reached 0.729. The AUC values for the other combinations also exceeded 0.65. While the Random Forest and XGBoost models performed slightly lower, they still demonstrated strong classification abilities, with AUCs ranging from 0.63 to 0.72. SHAP analysis revealed that key features, such as tumor texture and peritumoral gray-level features, significantly contributed to the model's classification decisions. The combination of multimodal imaging data with peritumoral features moderately improved the accuracy of prostate cancer classification. This model provides a non-invasive and effective diagnostic tool for clinical use and supports future personalized treatment decisions.

Machine learning (ML) algorithms play a crucial role in the early and accurate diagnosis of Alzheimer's Disease (AD), which is essential for effective treatment planning. However, existing methods are not well-suited for identifying Mild Cognitive Impairment (MCI), a critical transitional stage between normal aging and AD. This inadequacy is primarily due to label imbalance and bias from different sensitve attributes in MCI classification. To overcome these challenges, we have designed an end-to-end fairness-aware approach for label-imbalanced classification, tailored specifically for neuroimaging data. This method, built on the recently developed FACIMS framework, integrates into STREAMLINE, an automated ML environment. We evaluated our approach against nine other ML algorithms and found that it achieves comparable balanced accuracy to other methods while prioritizing fairness in classifications with five different sensitive attributes. This analysis contributes to the development of equitable and reliable ML diagnostics for MCI detection.